Tumor Necrosis Factor–Blocking Agents in Polymyalgia Rheumatica and Giant Cell Arteritis

  1. Carlo Salvarani, MD; and
  2. Gene G. Hunder
  1. From Arcispedale S. Maria Nuova, Reggio Emilia, 42100, Italy; and Mayo Clinic, Rochester, MN 55905.

    TO THE EDITOR:

    We agree with the conclusions of the insightful editorial by Luqmani (1) about the 2 randomized, controlled trials (RCTs) of infliximab in polymyalgia rheumatica (2) and giant cell arteritis (GCA) (3), especially that corticosteroids are still the cornerstone of treatment for these 2 related diseases. However, although these 2 studies showed that adding infliximab to prednisone is of no benefit in patients with GCA or polymyalgia rheumatica, a corticosteroid-sparing effect for tumor necrosis factor (TNF) …

    [Full Text of this Article]
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med January 15, 2008 vol. 148 no. 2 167-168
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues